• Duygu Demiroz, Yusuf Ziya Colak, Sumeyye Koc Iclek, ErdoganMehmet AliMAhttps://orcid.org/0000-0002-3860-6919Inonu University, School of Medicine, Department of Anesthesiology and Reanimation, Malatya, Turkey., Neslihan Altunkaya Yagci, Mahmut Durmus, and Nurcın Gulhas.
• Inonu University, School of Medicine, Department of Anesthesiology and Reanimation, Malatya, Turkey.
• Int. J. Clin. Pract. 2022 Jan 1; 2022: 6840960.

MethodsThis is a prospective, observational study. Patients between the ages of 18 and 65 with BMI of 18.5-34.9, who are expected to be under general anesthesia for less than 6 hours, were divided into 3 groups according to their BMI (Group 1 BMI = 18.5-24.9, Group 2 BMI = 25-29.9, Group 3 BMI = 30-34.9). These groups were randomly divided into 2 subgroups: Groups LBW; 1 LBW, 2 LBW, and 3 LBW were given rocuronium intubation dosages based on their LBW while control groups; 1K, 2K, and 3K were given 0.6 mg/kg rocuronium according to their total body weight. The data on the duration of action of rocuronium and its effects on the endotracheal intubation conditions were evaluated.ResultsIn Group 1, T1 time was found to be significantly longer (p=0.001). Intubation score and the use of additional rocuronium dose were found to be significantly higher in Group 1 LBW than in Group 1K (p=0.001). In Group 1, an additional rocuronium dose was needed to achieve optimal intubation conditions for subgroup 1 LBW. Rocuronium duration of action was found to be significantly longer in control groups 2 and 3, that received TBW-based dosage.ConclusionIn adult patients with a BMI of 18.5 and 24.9 BMI, we report optimal intubation conditions with the LBW-adjusted rocuronium dosage. This trial is registered with NCT05476952.Copyright © 2022 Duygu Demiroz et al.

14 keywords...

hide…